Event Date/Time: Jan 31, 2011 | End Date/Time: Feb 01, 2011 |
Description
It is now clear that the use of Biomarkers is an integral part in the future of medicine. With rising development costs and a declining rate of new drug discovery, pharmaceutical companies are now incorporating Biomarker strategies into all new R&D processes.
Key areas that will be addressed are: Bioinformatics, Preclinical Biomarker R&D, Translational Biomarkers, and Personalised Medicine.
Our exceptional speaker line-up includes:
• Hans Winkler, Senior Director and Global Head, Oncology Biomarkers, Johnson & Johnson
• Mark Fidock, Associate Research Fellow, Head of Quantitative Biomarkers, Pfizer
• Huseyin Mehmet, Director of Exploratory Biomarkers, Diabetes, Merck
• Fernando Ulloa-Montoya, Head of Molecular Biology Technology Group, GlaxoSmithKline
• Ziad Taib, Statistical Science Director, Astrazeneca
• Karen Asin, Director, Translational Pharmacology, Takeda
• Andrew Payne, Senior Group Leader, Cellular Sciences, UCB
• Ge Ruigt, Director Experimental Medicine Neuroscience, Merck
And much more....